Collegium Pharmaceutical Inc (COLL)
32.44
-1.23
(-3.65%)
USD |
NASDAQ |
May 17, 16:00
32.44
0.00 (0.00%)
After-Hours: 20:00
Collegium Pharmaceutical Research and Development Expense (Quarterly)
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| June 30, 2023 | 0.00 |
| March 31, 2023 | |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 3.983M |
| December 31, 2021 | 1.609M |
| September 30, 2021 | 1.45M |
| June 30, 2021 | 3.462M |
| March 31, 2021 | 2.93M |
| December 31, 2020 | 2.472M |
| September 30, 2020 | 2.141M |
| June 30, 2020 | 2.493M |
| March 31, 2020 | 2.666M |
| December 31, 2019 | 2.398M |
| September 30, 2019 | 2.491M |
| June 30, 2019 | 2.459M |
| March 31, 2019 | 2.992M |
| Date | Value |
|---|---|
| December 31, 2018 | 2.249M |
| September 30, 2018 | 1.907M |
| June 30, 2018 | 2.237M |
| March 31, 2018 | 2.268M |
| December 31, 2017 | 2.194M |
| September 30, 2017 | 2.069M |
| June 30, 2017 | 2.179M |
| March 31, 2017 | 2.13M |
| December 31, 2016 | 3.331M |
| September 30, 2016 | 3.254M |
| June 30, 2016 | 4.301M |
| March 31, 2016 | 4.062M |
| December 31, 2015 | 1.531M |
| September 30, 2015 | 3.358M |
| June 30, 2015 | 1.641M |
| March 31, 2015 | 1.445M |
| December 31, 2014 | 2.307M |
| September 30, 2014 | 5.818M |
| June 30, 2014 | 3.565M |
| March 31, 2014 | 3.269M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
Jun 2022
3.983M
Maximum
Mar 2022
1.697M
Average
2.270M
Median
Research and Development Expense (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | 2.581M |
| Supernus Pharmaceuticals Inc | 24.93M |
| AnaptysBio Inc | 37.04M |
| Recursion Pharmaceuticals Inc | 67.56M |
| Nuvalent Inc | 38.63M |